JP2012508734A - Ｂａｃｅ阻害剤としての置換イソインドール類及びそれらの使用 - Google Patents

Ｂａｃｅ阻害剤としての置換イソインドール類及びそれらの使用 Download PDF

Info

Publication number
JP2012508734A
JP2012508734A JP2011536289A JP2011536289A JP2012508734A JP 2012508734 A JP2012508734 A JP 2012508734A JP 2011536289 A JP2011536289 A JP 2011536289A JP 2011536289 A JP2011536289 A JP 2011536289A JP 2012508734 A JP2012508734 A JP 2012508734A
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
fluoro
pyridyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011536289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508734A5 (https=
Inventor
イェルク・ホーレンツ
ソフィア・カールストレム
カリン・コルモディン
ヨハン・リンドストレム
ラースロ・ラコス
ディディエ・ロッティッシ
ペーテル・セーデルマン
ブリット−マリエ・スヴァーン
ベルク シュテファン・フォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42170158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012508734(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2012508734A publication Critical patent/JP2012508734A/ja
Publication of JP2012508734A5 publication Critical patent/JP2012508734A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2011536289A 2008-11-14 2009-11-13 Ｂａｃｅ阻害剤としての置換イソインドール類及びそれらの使用 Pending JP2012508734A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11463408P 2008-11-14 2008-11-14
US61/114,634 2008-11-14
US13976708P 2008-12-22 2008-12-22
US61/139,767 2008-12-22
US22165309P 2009-06-30 2009-06-30
US61/221,653 2009-06-30
PCT/SE2009/051295 WO2010056196A1 (en) 2008-11-14 2009-11-13 New compounds 578

Publications (2)

Publication Number Publication Date
JP2012508734A true JP2012508734A (ja) 2012-04-12
JP2012508734A5 JP2012508734A5 (https=) 2012-12-20

Family

ID=42170158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536289A Pending JP2012508734A (ja) 2008-11-14 2009-11-13 Ｂａｃｅ阻害剤としての置換イソインドール類及びそれらの使用

Country Status (24)

Country Link
US (2) US8030500B2 (https=)
EP (1) EP2367814A4 (https=)
JP (1) JP2012508734A (https=)
KR (1) KR20110091540A (https=)
CN (1) CN102282140A (https=)
AR (1) AR074341A1 (https=)
AU (1) AU2009314664A1 (https=)
BR (1) BRPI0921879A2 (https=)
CA (1) CA2743938A1 (https=)
CL (1) CL2011001098A1 (https=)
CO (1) CO6362004A2 (https=)
CR (1) CR20110255A (https=)
CU (1) CU20110106A7 (https=)
DO (1) DOP2011000138A (https=)
EA (1) EA201190020A1 (https=)
EC (1) ECSP11011051A (https=)
IL (1) IL212590A0 (https=)
MX (1) MX2011004918A (https=)
NI (1) NI201100099A (https=)
PE (1) PE20110875A1 (https=)
TW (1) TW201020244A (https=)
UY (1) UY32241A (https=)
WO (1) WO2010056196A1 (https=)
ZA (1) ZA201104396B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2416603C9 (ru) 2005-10-25 2012-06-20 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина
TW200815349A (en) * 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
TWI488852B (zh) 2009-12-11 2015-06-21 Shionogi & Co 衍生物
WO2011142716A1 (en) * 2010-05-12 2011-11-17 Astrazeneca Ab Novel hemifumarate salt of isoindole compound acting as bace inhibitor
WO2012019056A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
US20120165346A1 (en) * 2010-12-22 2012-06-28 Astrazeneca Ab Compounds and their use as BACE inhibitors
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
WO2016160703A1 (en) 2015-03-27 2016-10-06 Harrup Mason K All-inorganic solvents for electrolytes
CN105272884B (zh) * 2015-11-02 2017-05-24 浙江大学 一种邻氰基二苯甲酮衍生物的制备方法
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149033A1 (en) * 2006-06-22 2007-12-27 Astrazeneca Ab Substituted isoindoles as bace inhibitors and their use
JP2008526966A (ja) * 2005-01-14 2008-07-24 ワイス β−セクレターゼの阻害のためのアミノ−イミダゾロン

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) * 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
AU702293B2 (en) * 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
DE4419849A1 (de) * 1994-06-07 1995-12-14 Hoechst Ag Isoindolinpigmente
WO1995034563A1 (en) 1994-06-16 1995-12-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
DE19516804A1 (de) 1995-05-08 1996-11-14 Hoechst Ag Isoindolinpigmente auf Basis von Aminochinoxalindionen
US5942400A (en) * 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
US6211235B1 (en) * 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
EP1012151B1 (en) 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
CN1300320C (zh) 1998-09-24 2007-02-14 法玛西雅厄普约翰美国公司 阿尔茨海默氏疾病分泌酶
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
CN1390232A (zh) 1999-02-10 2003-01-08 艾兰制药公司 人β分泌酶、抑制剂、其组合物和用途
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
EP1192177A1 (en) 1999-06-15 2002-04-03 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
PT1224297E (pt) 1999-09-23 2009-08-17 Pharmacia & Upjohn Co Llc Secretase da doença de alzheimer, seus substratos app e suas utilizações
GB9924957D0 (en) 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1299352B1 (en) 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
AU2001281250A1 (en) 2000-08-11 2002-02-25 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
US7630838B2 (en) 2000-09-22 2009-12-08 American Home Products Corporation Method for identifying agents that interact with beta-site APP cleaving enzyme (BACE)
PT1699455E (pt) 2003-12-15 2013-08-27 Merck Sharp & Dohme Inibidores de protease de aspartilo heterocíclicos
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2007530696A (ja) 2004-03-30 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド アスパラギン酸プロテアーゼ阻害剤として有用な２−アミノチアゾール化合物
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
BRPI0512213A (pt) * 2004-06-16 2008-02-19 Wyeth Corp método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
CA2578600A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
MX2007003336A (es) 2004-09-21 2007-06-05 Athersys Inc Acidos aceticos de indol que muestran antagonismo de receptor crth2 y usos de los mismos.
EP1802587A4 (en) 2004-10-15 2010-02-17 Astrazeneca Ab SUBSTITUTED AMINO BINDINGS AND THEIR APPLICATIONS
WO2006041405A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-pyrimidones and uses thereof
EP1831170A4 (en) 2004-12-14 2009-10-14 Astrazeneca Ab SUBSTITUTED AMINOPYRIDINES AND THEIR USE
ES2400287T3 (es) 2005-03-14 2013-04-08 High Point Pharmaceuticals, Llc Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa
RU2008100164A (ru) * 2005-06-14 2009-07-20 Шеринг Корпорейшн (US) Получение и применение соединений в качестве ингибиторов протеаз
AU2006259609A1 (en) 2005-06-14 2006-12-28 Pharmacopeia, Inc. Aspartyl protease inhibitors
MX2007016180A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
CA2609562A1 (en) * 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
CN101198597B (zh) 2005-06-14 2011-11-16 先灵公司 作为天冬氨酰基蛋白酶抑制剂的化合物的制备和用途
MX2007016186A (es) 2005-06-14 2008-03-07 Schering Corp Preparacion y uso de inhibidores de proteasas.
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
WO2007005404A1 (en) * 2005-06-30 2007-01-11 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
US8211904B2 (en) 2005-07-18 2012-07-03 Merck, Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US7601751B2 (en) * 2005-09-01 2009-10-13 Bristol-Myers Squibb Company Indole acetic acid acyl guanidines as β-secretase inhibitors
RU2416603C9 (ru) 2005-10-25 2012-06-20 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина
WO2007050721A2 (en) * 2005-10-27 2007-05-03 Schering Corporation Heterocyclic aspartyl protease inhibitors
PE20070798A1 (es) * 2005-10-31 2007-08-24 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
CN101360720A (zh) 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶酮衍生物及其用途
WO2007058582A1 (en) 2005-11-15 2007-05-24 Astrazeneca Ab Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use
JP2009515950A (ja) 2005-11-15 2009-04-16 アストラゼネカ・アクチエボラーグ 新規な２−アミノピリミジン誘導体およびその使用
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
JP2009520686A (ja) 2005-11-21 2009-05-28 アストラゼネカ・アクチエボラーグ 新規な２−アミノ−イミダゾール−４−オン化合物並びに認知障害、アルツハイマー病、神経変性及び認知症の治療に使用する医薬の製造におけるその使用
AR058381A1 (es) 2005-12-19 2008-01-30 Astrazeneca Ab Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
US20090099217A1 (en) 2006-04-05 2009-04-16 Astex Therapeutics Ltd. 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
KR20090015967A (ko) 2006-06-12 2009-02-12 쉐링 코포레이션 헤테로사이클릭 아스파르틸 프로테아제 억제제
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
WO2008063114A1 (en) 2006-11-20 2008-05-29 Astrazeneca Ab Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
TW200902499A (en) * 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
WO2009005470A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005471A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
US20100125081A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 574
US20100125087A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
EP2485590B1 (en) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526966A (ja) * 2005-01-14 2008-07-24 ワイス β−セクレターゼの阻害のためのアミノ−イミダゾロン
WO2007149033A1 (en) * 2006-06-22 2007-12-27 Astrazeneca Ab Substituted isoindoles as bace inhibitors and their use

Also Published As

Publication number Publication date
CA2743938A1 (en) 2010-05-20
US20100125082A1 (en) 2010-05-20
BRPI0921879A2 (pt) 2018-10-16
CR20110255A (es) 2011-07-04
EA201190020A1 (ru) 2012-02-28
CL2011001098A1 (es) 2012-02-24
AR074341A1 (es) 2011-01-12
CO6362004A2 (es) 2012-01-20
CN102282140A (zh) 2011-12-14
DOP2011000138A (es) 2011-06-30
AU2009314664A1 (en) 2011-06-23
US8030500B2 (en) 2011-10-04
WO2010056196A1 (en) 2010-05-20
US20110319426A1 (en) 2011-12-29
UY32241A (es) 2010-06-30
EP2367814A1 (en) 2011-09-28
IL212590A0 (en) 2011-07-31
ZA201104396B (en) 2012-03-28
CU20110106A7 (es) 2012-01-31
TW201020244A (en) 2010-06-01
KR20110091540A (ko) 2011-08-11
ECSP11011051A (es) 2011-06-30
PE20110875A1 (es) 2012-01-11
NI201100099A (es) 2012-03-19
MX2011004918A (es) 2011-05-30
EP2367814A4 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
JP2012508734A (ja) Ｂａｃｅ阻害剤としての置換イソインドール類及びそれらの使用
US20100125081A1 (en) New compounds 574
US20100125087A1 (en) New compounds 575
US20080161269A1 (en) Compounds 620
JP5189074B2 (ja) ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
DK3044221T3 (en) 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ON COMPOUNDS AND THERAPEUTIC APPLICATION THEREOF
US20080176862A1 (en) New Compounds 617
US20090233943A9 (en) New compounds 835
JP2009539976A (ja) アミノイミダゾロン類、ならびに認知機能障害、アルツハイマー病、神経変性および認知症を治療するための医薬品としてのそれらの使用
US20080171771A1 (en) New Compounds 391
JP2009539975A (ja) アミノイミダゾロン類、および、認知機能障害、アルツハイマー病、神経変性および認知症を治療するための医薬品としてのそれらの使用
JP2009539973A (ja) アミノイミダゾロン類、および、認知機能障害、アルツハイマー病、神経変性および認知症を治療するための医薬品としてのそれらの使用
TW200902499A (en) New compounds
US20080051420A1 (en) New Compounds 317
US10954232B2 (en) Pyrazole derivative as ALK5 inhibitor and uses thereof
WO2011002409A1 (en) 5h-pyrrolo[3,4-£>]pyrazin-7-amine derivatives inhibitors of beta-secretase
JP2004514712A (ja) 抗炎症剤としての４，６−ジフェニルピリジン誘導体
TW201105650A (en) New compounds
TW201014852A (en) Indolizine inhibitors of leukotriene production
US20120165346A1 (en) Compounds and their use as BACE inhibitors
HK1164846A (en) New compounds 578
CN101506162B (zh) 作为β位淀粉样前体蛋白裂解酶抑制剂的取代的异吲哚和它们的用途
CN101501040A (zh) 氨基-咪唑啉以及它们作为治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物的用途
WO2022166468A1 (zh) Bruton's酪氨酸激酶抑制剂及其应用
CN101506212A (zh) 氨基-咪唑酮及其作为治疗认知缺损、阿尔兹海默病、神经变性和痴呆的药物的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140708